MedTrace Logo

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

NCT04910100 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2024-04-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions. These eye drops will be compared to timolol 0.5 percent eye drop solution in participants with open angle glaucoma (the most common type of glaucoma) or high eye pressure (ocular hypertension).

Conditions

Interventions

DRUG

Nebivolol Ophthalmic Suspension 1 Percent

1 drop instilled into each eye twice daily

DRUG

Nebivolol Ophthalmic Suspension 0.5 Percent

1 drop instilled into each eye twice daily

DRUG

Timolol Ophthalmic Suspension 0.5 Percent

1 drop instilled into each eye twice daily

DRUG

Timolol Ophthalmic Solution 0.5 Percent

1 drop instilled into each eye twice daily

Sponsors & Collaborators

  • Trial Runners, LLC

    collaborator OTHER

  • Summit Analytical LLC

    collaborator INDUSTRY

  • Betaliq, Inc.

    lead INDUSTRY

Principal Investigators

  • Kristin Peterson · Trial Runners, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2022-03-31
Completion
2022-04-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910100 on ClinicalTrials.gov